Ten years with biologics: to whom do data on effectiveness and safety apply? - Wikidata - wikimedia - TriplyDB

Ten years with biologics: to whom do data on effectiveness and safety apply?

Ten years with biologics: to whom do data on effectiveness and safety apply?

http://www.wikidata.org/entity/Q33749195

about

Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Comparative effectiveness research with administrative health data in rheumatoid arthritis.Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy.Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.A nurse-led rheumatology clinic versus rheumatologist-led clinic in monitoring of patients with chronic inflammatory arthritis undergoing biological therapy: a cost comparison study in a randomised controlled trial.Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study.Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?Emerging cell and cytokine targets in rheumatoid arthritis.Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].'Rheumatologist go home!' Coming up next?Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis.The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.Creating a culture of health: evolving healthcare systems and patient engagement.Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice.Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions

P2860

Q26778600-06245AFB-DC9F-43B2-887C-5A0E3FDDC41B Q31077662-36334DF7-E132-44B4-9317-B8EC14000FD5 Q34850808-99648DD4-19E9-4226-8A85-146DCAF51474 Q35038322-3F02C929-989F-432C-A4C1-883EC5BC3145 Q35048347-4305C36D-2E3C-4EF4-83E0-DA5B8C66F5EA Q35843240-F7DEBB62-763A-4B88-A057-3402D42600AA Q36081041-1CC5F57B-E82A-4784-92CF-BA2F76FB54F5 Q37838346-C6C5A926-926B-4A68-9320-7690629CEB12 Q37865413-D88EDDC8-4A1B-4DC2-B4DE-45C7D436E17D Q38161794-54C780D0-8B64-4375-A715-657603932C53 Q40209526-1372A0D7-AFA9-4A72-B243-2F6328480267 Q41176187-F6157455-5E48-43F7-B747-DD6BDAFA250A Q44376708-E87EB40D-3060-4F29-A4B3-6E7809632FD4 Q46129663-77E7C719-C949-435C-BC7D-523F2254DCF9 Q46131525-A67B8AC0-370D-40C4-A78C-4B365B9F4809 Q46894147-41EC2D00-3372-47D2-88E6-B7A2FC440CCC Q47114261-EC28070A-17A1-4385-BB2D-EF58ECE7CF54 Q47122664-9E5D72E5-93E0-476B-B8DF-07908CCADA4D Q50091508-F1104EBF-6201-41D9-80AB-9DFDD12F52E4 Q50480103-F2EA5495-85D9-4129-9B71-83A0BDC14BA0 Q50591145-B21A2C9E-30EA-4D3E-BBC1-0C91754E50DC Q52653996-D1CC7603-20BA-4C44-83BA-1E5736509C4C Q53119214-B5BB4868-2703-446A-8FFF-B1B09268C42D Q53654897-91B49100-8D86-480F-A5DD-2F598370BE9C Q56835543-4525F6CE-9093-4008-A7AE-22C337896200

P2860

Ten years with biologics: to whom do data on effectiveness and safety apply?

http://www.wikidata.org/entity/Q33749195

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Ten years with biologics: to whom do data on effectiveness and safety apply?

@ast

Ten years with biologics: to whom do data on effectiveness and safety apply?

@en

type

label

Ten years with biologics: to whom do data on effectiveness and safety apply?

@ast

Ten years with biologics: to whom do data on effectiveness and safety apply?

@en

prefLabel

Ten years with biologics: to whom do data on effectiveness and safety apply?

@ast

Ten years with biologics: to whom do data on effectiveness and safety apply?

@en

P1433

Q33749195-37A35515-C770-4364-B2C4-8F8574D88543

P1476

Q33749195-0E461836-9976-4584-99AA-D2495AC2EA60

P2093

Q33749195-05234531-9239-4FF7-A358-FB9A6CC011D2

Q33749195-178AE132-29A8-480D-8800-251AC19CB8A6

Q33749195-4825794A-9424-4790-A2D9-DCEA15B04E14

Q33749195-70ADD279-D943-4210-AC6C-D294455C899E

Q33749195-84D11FDF-745A-41AC-8CDC-9089A9F501A9

Q33749195-90A1BC1E-C130-4F57-9AF6-99E66BEAE60C

Q33749195-A4BF74C9-33FC-4B22-81B8-8D382FB90933

Q33749195-BB46E434-2B7F-4AA4-BB0D-20627FF34F5C

Q33749195-EF3AF1B5-99C8-46CF-BB28-13B25725AE20

Q33749195-F89606CF-3CC1-4CCC-867D-72F4EC1912A0

P2860

Q33749195-12C473FA-4827-44CC-9F77-14F76E09AAC0

Q33749195-3E9110F7-69A6-4975-86BA-A2878009D295

Q33749195-4AB54E65-F54E-4C2A-B6D4-ADC2AEA50C92

Q33749195-5032E9B5-D7E1-4B82-BB40-CA204B9EBD33

Q33749195-91913E87-7F34-4FF6-82AF-0215B62D83EE

Q33749195-9518B758-1705-4B80-86D2-392A3EA4BA18

Q33749195-C32194E8-5276-4C1C-87A7-50B8F358DB93

Q33749195-CDD73B21-465B-402E-B69D-9CA0C8B71633

P304

Q33749195-22E4ECFB-26C2-4880-B5D2-8687CC444469

P31

Q33749195-18106EA8-4403-43DA-AB0A-A5567D7BF749

P356

Q33749195-DF236C81-A9D1-40E4-9C58-04281B1101C3

P433

Q33749195-95CA1532-337E-4FBA-B974-EDE279EBA16E

P478

Q33749195-DC50F281-5194-4EDE-891B-FC922B413978

P50

Q33749195-3817FF37-1CDC-4559-829F-5192D149403C

Q33749195-4A00D1A8-6527-4D10-BB86-FD4D4D3F194F

Q33749195-8460B995-AB76-413E-948B-648D43667CDA

Q33749195-ADD33F35-9D57-42B3-A426-B6BA9A1195EB

Q33749195-D2339F21-01CB-4D6D-A6D3-B84D9E57B811

Q33749195-F352551B-4F43-4B2C-8E2C-42BDAF64BBB4

P577

Q33749195-FFC2296B-7FCF-45B4-862C-64C9F4054409

P698

Q33749195-AE5A4C63-7206-4F67-B026-B13BB34EE6B6

P356

P1433

P1476

Ten years with biologics: to whom do data on effectiveness and safety apply?

@en

P2093

Anders Sundström

http://www.w3.org/2001/XMLSchema#string

Christina Dackhammar

http://www.w3.org/2001/XMLSchema#string

Eva Baecklund

http://www.w3.org/2001/XMLSchema#string

Johan Askling

http://www.w3.org/2001/XMLSchema#string

Lars Coster

http://www.w3.org/2001/XMLSchema#string

Lennart Jacobsson

http://www.w3.org/2001/XMLSchema#string

Nils Feltelius

http://www.w3.org/2001/XMLSchema#string

Pierre Geborek

http://www.w3.org/2001/XMLSchema#string

Staffan Lindblad

http://www.w3.org/2001/XMLSchema#string

Tore Saxne

http://www.w3.org/2001/XMLSchema#string

P2860

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent.

Swedish registers to examine drug safety and clinical issues in RA.

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Infections in patients with rheumatoid arthritis treated with biologic agents.

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

P304

204-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEQ326

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Solbritt Rantapää-Dahlqvist

Ronald van Vollenhoven

Elizabeth V Arkema

P577

2010-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21084326

http://www.w3.org/2001/XMLSchema#string